Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc.

AMLX·NASDAQ

$14.31

+7.7%
HealthcareBiotechnology

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$1.19B
EPS-1.5300
P/E Ratio-9.35
Earnings Date08/06/2026

amlx

Other Financing Activities

Last Annual Value

-3.36M

3-Year CAGR

-72%

5-Year CAGR

-135%

10-Year CAGR

-62%

Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. Competitors Analysis of Other Financing Activities

AMLX · NASDAQ
CompanyOther Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
-3.36M
N/AN/AN/A 
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
PGEN logo
Precigen, Inc.
NASDAQ:PGEN
-3.08M
N/AN/AN/A
-21.66M
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. Fair Value Envelope

AMLX · NASDAQ

Our analysis suggests that AMLX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $14.31, this represents a potential HIDDEN relative to our calculated worth for Amylyx Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $14.31